Cadherins are transmembrane glycoproteins involved in cell-cell adherence. Recent developments indicate that classical cadherins may act as adherence-activated signaling receptors. Here, we review recent data from the literature concerning the role of classical cadherins in the control of cell survival and the signaling pathways involved. We focus on the fate and the role of E-cadherin, the main classical cadherin expressed in epithelial cells, in the cell death program triggered in enterocytes by loss of anchorage from the extracellular matrix (anoikis). These data open new perspectives on the key role of this protein, which is dysregulated in most carcinoma and is considered as a tumour-suppressor.
Download full-text PDF |
Source |
---|
Am J Surg Pathol
January 2025
Instituto de Anatomia Patológica, Faculdade de Medicina da Universidade de Lisboa.
E-cadherin (E-cad) immunohistochemistry is commonly used to distinguish lobular carcinoma in situ (LCIS) from ductal carcinoma in situ in histologically uncertain or ambiguous cases. Although most LCIS cases show an absence of E-cad expression on the neoplastic cell membranes, some show aberrant E-cad expression which can lead to diagnostic confusion. Awareness and understanding of the frequency, patterns, and distribution of aberrant E-cad staining in LCIS is crucial to achieving a correct diagnosis.
View Article and Find Full Text PDFJ Mol Cell Cardiol Plus
September 2024
National Research Center for Preventive Medicine (NRCPM), Petroverigsky, 10, building 3, Moscow 101990, Russia.
Background And Aims: Cadherins are adhesion proteins, and their dysregulation may result in the development of atherosclerosis, plaque rupture, or lesions of the vascular wall. The aim of the present study was to detect the associations of cadherins-P, -E, and -H, with atherosclerosis and pathological cardiovascular conditions.
Methods And Results: The present study with 3-year follow up evaluated atherosclerosis and fasting levels of P-, E-, and H-cadherins in the serum samples of 214 patients in a hospital setting.
Pathologica
October 2024
Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.
Invasive lobular carcinoma of the breast is the most common special type breast cancer. It has been defined using morphological features, has a characteristic immunophenotype associated with the loss of E-cadherin mediated intercellular adhesion, and the background of this immunohistochemistry and morphology is generally a biallelic genetic alteration of the CDH-1 gene coding E-cadherin. However, the morphology may often deviate from the classical, and immunohistochemistry may also deviate from the typical, and then the diagnosis of invasive lobular carcinoma becomes less straight forward.
View Article and Find Full Text PDFExp Oncol
December 2024
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Background: The ability to metabolic reprogramming is a distinctive feature of metastatically active tumor cells. A classic example of metabolic reprogramming, characteristic of almost all malignant cells, is aerobic glycolysis. Therefore, inhibition of glycolysis in tumor cells is considered a promising strategy for antitumor therapy.
View Article and Find Full Text PDFCrit Rev Oncol Hematol
December 2024
Department of Pharmacy, The University of Lahore, Sargodha campus, Sargodha, Punjab, Pakistan. Electronic address:
Current therapeutic strategies for benign prostatic hyperplasia (BPH) and prostate cancer focus mainly on androgen receptors (AR) and 5-alpha reductase inhibition to suppress androgen-driven prostate growth. However, these methods often result in side effects and resistance. Recent research identifies novel targets like integrin and cadherin inhibitors, gene regulation, microRNAs, cellular senescence, and metabolomics pathways to overcome these limitations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!